Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study

M. Javle; J. Yu; C. Garrett; A. Pande; B. Kuvshinoff; A. Litwin; J. Phelan; J. Gibbs; R. Iyer

doi:10.1038/sj.bjc.6605099

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study

M. Javle
, J. Yu
, C. Garrett
, A. Pande
, B. Kuvshinoff
, A. Litwin
, J. Phelan
, J. Gibbs
, R. Iyer

Department of Biostatistics

Roswell Park Cancer Institute
University of Texas MD Anderson Cancer Center
Moffitt Cancer Center
Lipson Cancer Center

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg¹, capecitabine 1300mgm ² daily for 2 weeks and gemcitabine 1000mgm² weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22), thrombocytopaenia (14), thromboembolic events (12), hypertension (8) and haemorrhage (6).

Original language	English
Pages (from-to)	1842-1845
Number of pages	4
Journal	British Journal of Cancer
Volume	100
Issue number	12
DOIs	https://doi.org/10.1038/sj.bjc.6605099
State	Published - Jun 16 2009

Keywords

Bevacizumab
Capecitabine
Chemotherapy
Gemcitabine
Metastatic
Pancreatic cancer

Access to Document

10.1038/sj.bjc.6605099

Cite this

@article{20979d38f2a147fd92683af36229745e,

title = "Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study",

abstract = "A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg1, capecitabine 1300mgm 2 daily for 2 weeks and gemcitabine 1000mgm2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22), thrombocytopaenia (14), thromboembolic events (12), hypertension (8) and haemorrhage (6).",

keywords = "Bevacizumab, Capecitabine, Chemotherapy, Gemcitabine, Metastatic, Pancreatic cancer",

author = "M. Javle and J. Yu and C. Garrett and A. Pande and B. Kuvshinoff and A. Litwin and J. Phelan and J. Gibbs and R. Iyer",

year = "2009",

month = jun,

day = "16",

doi = "10.1038/sj.bjc.6605099",

language = "English",

volume = "100",

pages = "1842--1845",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "12",

}

TY - JOUR

T1 - Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer

T2 - A phase II study

AU - Javle, M.

AU - Yu, J.

AU - Garrett, C.

AU - Pande, A.

AU - Kuvshinoff, B.

AU - Litwin, A.

AU - Phelan, J.

AU - Gibbs, J.

AU - Iyer, R.

PY - 2009/6/16

Y1 - 2009/6/16

N2 - A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg1, capecitabine 1300mgm 2 daily for 2 weeks and gemcitabine 1000mgm2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22), thrombocytopaenia (14), thromboembolic events (12), hypertension (8) and haemorrhage (6).

AB - A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15mgkg1, capecitabine 1300mgm 2 daily for 2 weeks and gemcitabine 1000mgm2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22), thrombocytopaenia (14), thromboembolic events (12), hypertension (8) and haemorrhage (6).

KW - Bevacizumab

KW - Capecitabine

KW - Chemotherapy

KW - Gemcitabine

KW - Metastatic

KW - Pancreatic cancer

UR - https://www.scopus.com/pages/publications/67349250514

U2 - 10.1038/sj.bjc.6605099

DO - 10.1038/sj.bjc.6605099

M3 - Article

C2 - 19491904

AN - SCOPUS:67349250514

SN - 0007-0920

VL - 100

SP - 1842

EP - 1845

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 12

ER -

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: A phase II study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this